Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at ...

Pharmaceutical giant Novavax on Monday announced that the U.S. Food and Drug Administration (FDA) approved its COVID-19 ...

Novavax (NASDAQ:NVAX) shares jumped more than 17% on Monday after the U.S. Food and Drug Administration granted full approval ...

US FDA approves Novavax’s BLA for Covid-19 vaccine, Nuvaxovid: Gaithersburg, Maryland Tuesday, May 20, 2025, 14:00 Hrs [IST] Novavax, Inc. announced that the US Food and Drug Ad ...

The U.S. Food and Drug Administration approved the vaccine, Nuvaxovid, but limited its use to older adults and people over 12 ...

Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial ...